ERBB2 and gastroesophageal junction adenocarcinoma: We hypothesized that among patients with advanced G/GEJ adenocarcinoma, those with HER2 positivity might exhibit a better prognosis when treated with a combination of ICI, chemotherapy, and targeted HER2 therapy compared to HER2-negative patients treated with a combination of ICI and chemotherapy alone.